Circulating endothelin-1 is not increased in severe preeclampsia

Dinesh M. Shah, Marshall Frazer, Kamal F. Badr

Research output: Contribution to journalArticle

Abstract

Endothelin-1 is a potent vasoconstrictor peptide released by vascular endothelial cells. Preeclampsia is a unique hypertensive disorder of pregnancy. Endothelial (ET) cell injury has been implicated in the pathophysiology of this disorder. Endothelial cell injury has been shown in vitro to cause the release of endothelin-1. Therefore, we conducted a prospective study of pregnant patients with hypertensive disorders and a control population to examine whether circulating levels of endothelin-1 are elevated in these disorders. We studied 21 patients with the following diagnoses: severe preeclampsia (n = 9); chronic hypertension (n = 6), two of whom had superimposed preeclampsia; and control patients (n = 6). The mean maternal and gestational ages were similar in these three groups. More importantly, severe preeclamptic patients were selected by strict criteria and most had evidence of thrombocytopenia. Endothelin was extracted immediately after the collection of blood and measured by a standard radioimmunoassay (RIA). There were no differences between the endothelin-1 levels (mean ± SEM) in patients with severe preeclampsia (2.1 ± 0.6), in patients with chronic hypertension without superimposed preeclampsia (1.9 ± 0.8), and in the control population (1.7 ± 0.6). Our results are consistent with the current concept that endothelin-1 does not function as a circulating hormone. However, because of its prolonged duration of action and function as a locally acting hormone, demonstration of elevated circulating levels of ET-1 is not necessary to support its participation in the vasospasm of preeclampsia.

Original languageEnglish (US)
Pages (from-to)177-180
Number of pages4
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume1
Issue number4
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Endothelin-1
Pre-Eclampsia
Endothelial Cells
Hormones
Hypertension
Endothelins
Maternal Age
Wounds and Injuries
Vasoconstrictor Agents
Thrombocytopenia
Population
Gestational Age
Radioimmunoassay
Prospective Studies
Pregnancy
Peptides

Keywords

  • Endothelin-1
  • Preeclampsia
  • Pregnancy-induced hypertension

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Circulating endothelin-1 is not increased in severe preeclampsia. / Shah, Dinesh M.; Frazer, Marshall; Badr, Kamal F.

In: Journal of Maternal-Fetal and Neonatal Medicine, Vol. 1, No. 4, 1992, p. 177-180.

Research output: Contribution to journalArticle

Shah, Dinesh M. ; Frazer, Marshall ; Badr, Kamal F. / Circulating endothelin-1 is not increased in severe preeclampsia. In: Journal of Maternal-Fetal and Neonatal Medicine. 1992 ; Vol. 1, No. 4. pp. 177-180.
@article{75d90fd92d8441ff9dcb65d4d1e7cd7b,
title = "Circulating endothelin-1 is not increased in severe preeclampsia",
abstract = "Endothelin-1 is a potent vasoconstrictor peptide released by vascular endothelial cells. Preeclampsia is a unique hypertensive disorder of pregnancy. Endothelial (ET) cell injury has been implicated in the pathophysiology of this disorder. Endothelial cell injury has been shown in vitro to cause the release of endothelin-1. Therefore, we conducted a prospective study of pregnant patients with hypertensive disorders and a control population to examine whether circulating levels of endothelin-1 are elevated in these disorders. We studied 21 patients with the following diagnoses: severe preeclampsia (n = 9); chronic hypertension (n = 6), two of whom had superimposed preeclampsia; and control patients (n = 6). The mean maternal and gestational ages were similar in these three groups. More importantly, severe preeclamptic patients were selected by strict criteria and most had evidence of thrombocytopenia. Endothelin was extracted immediately after the collection of blood and measured by a standard radioimmunoassay (RIA). There were no differences between the endothelin-1 levels (mean ± SEM) in patients with severe preeclampsia (2.1 ± 0.6), in patients with chronic hypertension without superimposed preeclampsia (1.9 ± 0.8), and in the control population (1.7 ± 0.6). Our results are consistent with the current concept that endothelin-1 does not function as a circulating hormone. However, because of its prolonged duration of action and function as a locally acting hormone, demonstration of elevated circulating levels of ET-1 is not necessary to support its participation in the vasospasm of preeclampsia.",
keywords = "Endothelin-1, Preeclampsia, Pregnancy-induced hypertension",
author = "Shah, {Dinesh M.} and Marshall Frazer and Badr, {Kamal F.}",
year = "1992",
doi = "10.3109/14767059209161914",
language = "English (US)",
volume = "1",
pages = "177--180",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Circulating endothelin-1 is not increased in severe preeclampsia

AU - Shah, Dinesh M.

AU - Frazer, Marshall

AU - Badr, Kamal F.

PY - 1992

Y1 - 1992

N2 - Endothelin-1 is a potent vasoconstrictor peptide released by vascular endothelial cells. Preeclampsia is a unique hypertensive disorder of pregnancy. Endothelial (ET) cell injury has been implicated in the pathophysiology of this disorder. Endothelial cell injury has been shown in vitro to cause the release of endothelin-1. Therefore, we conducted a prospective study of pregnant patients with hypertensive disorders and a control population to examine whether circulating levels of endothelin-1 are elevated in these disorders. We studied 21 patients with the following diagnoses: severe preeclampsia (n = 9); chronic hypertension (n = 6), two of whom had superimposed preeclampsia; and control patients (n = 6). The mean maternal and gestational ages were similar in these three groups. More importantly, severe preeclamptic patients were selected by strict criteria and most had evidence of thrombocytopenia. Endothelin was extracted immediately after the collection of blood and measured by a standard radioimmunoassay (RIA). There were no differences between the endothelin-1 levels (mean ± SEM) in patients with severe preeclampsia (2.1 ± 0.6), in patients with chronic hypertension without superimposed preeclampsia (1.9 ± 0.8), and in the control population (1.7 ± 0.6). Our results are consistent with the current concept that endothelin-1 does not function as a circulating hormone. However, because of its prolonged duration of action and function as a locally acting hormone, demonstration of elevated circulating levels of ET-1 is not necessary to support its participation in the vasospasm of preeclampsia.

AB - Endothelin-1 is a potent vasoconstrictor peptide released by vascular endothelial cells. Preeclampsia is a unique hypertensive disorder of pregnancy. Endothelial (ET) cell injury has been implicated in the pathophysiology of this disorder. Endothelial cell injury has been shown in vitro to cause the release of endothelin-1. Therefore, we conducted a prospective study of pregnant patients with hypertensive disorders and a control population to examine whether circulating levels of endothelin-1 are elevated in these disorders. We studied 21 patients with the following diagnoses: severe preeclampsia (n = 9); chronic hypertension (n = 6), two of whom had superimposed preeclampsia; and control patients (n = 6). The mean maternal and gestational ages were similar in these three groups. More importantly, severe preeclamptic patients were selected by strict criteria and most had evidence of thrombocytopenia. Endothelin was extracted immediately after the collection of blood and measured by a standard radioimmunoassay (RIA). There were no differences between the endothelin-1 levels (mean ± SEM) in patients with severe preeclampsia (2.1 ± 0.6), in patients with chronic hypertension without superimposed preeclampsia (1.9 ± 0.8), and in the control population (1.7 ± 0.6). Our results are consistent with the current concept that endothelin-1 does not function as a circulating hormone. However, because of its prolonged duration of action and function as a locally acting hormone, demonstration of elevated circulating levels of ET-1 is not necessary to support its participation in the vasospasm of preeclampsia.

KW - Endothelin-1

KW - Preeclampsia

KW - Pregnancy-induced hypertension

UR - http://www.scopus.com/inward/record.url?scp=0004578837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0004578837&partnerID=8YFLogxK

U2 - 10.3109/14767059209161914

DO - 10.3109/14767059209161914

M3 - Article

AN - SCOPUS:0004578837

VL - 1

SP - 177

EP - 180

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

IS - 4

ER -